Spontaneous ARIA (Amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 44, Issue 4, 2015, Pages 1069-1074

  Ryan, Natalie S ^a   Lashley, Tammaryn ^a   Revesz, Tamas ^a   Dantu, Kiran ^b   Fox, Nick C ^a   Morris, Huw R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Ysbyty Ystrad Fawr Hospital ^*  (United Kingdom)

Author keywords

APOE; Cerebral amyloid angiopathy related inflammation; Familial Alzheimer's disease; Magnetic resonance imaging; Presenilin 1

Indexed keywords

ALPHA SYNUCLEIN; APOLIPOPROTEIN E4; CD68 ANTIGEN; CHOLINESTERASE INHIBITOR; PREDNISOLONE; PRESENILIN 1; QUETIAPINE; STEROID; PSEN1 PROTEIN, HUMAN;

ADULT; AGITATION; ALZHEIMER DISEASE; AMYLOID RELATED IMAGING ABNORMALITIES; ARTICLE; AUTOPSY; BRAIN ATROPHY; CASE REPORT; CD3+ T LYMPHOCYTE; CEREBRAL AMYLOID ANGIOPATHY RELATED INFLAMMATION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; FAMILIAL ALZHEIMER DISEASE; FEMALE; GENE MUTATION; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; MEMORY DISORDER; MIDDLE AGED; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RISK FACTOR; SEIZURE; SENILE PLAQUE; STEREOTYPY; VASCULAR AMYLOIDOSIS; VISUAL HALLUCINATION; COGNITION DISORDERS; COMPLICATION; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CEREBRAL AMYLOID ANGIOPATHY; COGNITION DISORDERS; FEMALE; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PRESENILIN-1;

EID: 84937044153     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142325     Document Type: Article

References (19)

1. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman B.T., Scheltens P., Carrillo MC, Thies W, Bednar MM, Black R.S., Brashear HR, Grundman M, Siemers ER, Feldman H.H., Schindler R.J. (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7, 367-385.
2. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M., Richter RW, Soininen H, Thein S, Shiovitz T., Pilcher G, Colby S, Rollin L., Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM (2012) Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69, 1430-1440.
3. Ostrowitzki S, Deptula D, Thurfjell L., Barkhof F, Bohrmann B, Brooks D.J., Klunk WE, Ashford E, Yoo K, Xu Z.X., Loetscher H., Santarelli L. (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69, 198-207.
4. Sperling R, Salloway S, Brooks D.J., Tampieri D., Barakos J, Fox NC, Raskind M, Sabbagh M., Honig LS, Porsteinsson AP, Lieberburg I, Arrighi H.M., Morris KA, Lu Y, Liu E, Gregg K.M., Brashear HR, Kinney GG, Black R, Grundman M (2012) Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol 11, 241-249.
5. Salloway S, Sperling R, Fox N.C., Blennow K., Klunk W, Raskind M, Sabbagh M., Honig LS, Porsteinsson AP, Ferris S, Reichert M., Ketter N, Nejadnik B, Guenzler V., Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370, 322-333.
6. Piazza F, Greenberg SM, Savoiardo M, Gardinetti M., Chiapparini L, Raicher I, Nitrini R., Sakaguchi H, Brioschi M, Billo G., Colombo A, Lanzani F, Piscosquito G., Carriero MR, Giaccone G, Tagliavini F, Ferrarese C, Di Francesco JC (2013) Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloidmodifying therapies. Ann Neurol 73, 449-458.
7. Bergeron C, Ranalli PJ, Miceli P.N. (1987) Amyloid angiopathy in Alzheimer's disease. Can J Neurol Sci 14, 564-569.
8. Carlson C, Estergard W, Oh J., Suhy J, Jack CR Jr, Siemers E, Barakos J. (2011) Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 7, 396-401.
9. Church A, Prescott J, Lillis S., Rees J, Chance P, Williamson K., Morris H.R. (2011) A novel presenilin 1 mutation, I202F occurring at a previously predicted pathogenic site causing autosomal dominant Alzheimer's disease. Neurobiol Aging 32, 556-552.
10. Greenberg SM, Frosch M.P. (2011) Life imitates art: Antiamyloid antibodies and inflammatory cerebral amyloid angiopathy. Neurology 76, 772-773.
11. Bogner S, Bernreuther C, Matschke J., Barrera-Ocampo A, Sepulveda-Falla D, Leypoldt F., Magnus T, Haag F, Bergmann M., Bruck W, Vogelgesang S, Glatzel M. (2014) Immune activation in amyloid-beta-related angiitis correlates with decreased parenchymal amyloid-beta plaque load. Neurodegener Dis 13, 38-44.
12. Melzer N, Harder A, Gross CC, Wolfer J, Stummer W, Niederstadt T, Meuth SG, Marziniak M, Grauer OM, Wiendl H (2012) CD4(+) T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid beta-related angiitis. Arch Neurol 69, 773-777.
13. DiFrancesco JC, Brioschi M, Brighina L., Ruffmann C, Saracchi E, Costantino G., Galimberti G, Conti E, Curto N.A., Marzorati L., Remida P, Tagliavini F, Savoiardo M., Ferrarese C. (2011) Anti-Abeta autoantibodies in the CSF of a patient with CAA-related inflammation: A case report. Neurology 76, 842-844.
14. Mann DM, Pickering-Brown SM, Takeuchi A., Iwatsubo T. (2001) Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 158, 2165-2175.
15. Eng JA, Frosch MP, Choi K, Rebeck G.W., Greenberg S.M. (2004) Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 55, 250-256.
16. Kinnecom C, Lev MH, Wendell L, Smith E.E., Rosand J., Frosch MP, Greenberg S.M. (2007) Course of cerebral amyloid angiopathy-related inflammation. Neurology 68, 1411-1416.
17. Thal DR, Ghebremedhin E, Rub U., Yamaguchi H, Del Tredici K, Braak H. (2002) Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61, 282-293.
18. Richard E, Carrano A, Hoozemans J.J., van Horssen J, van Haastert ES, Eurelings LS, de Vries HE, Thal DR, Eikelenboom P, van Gool WA, Rozemuller AJ (2010) Characteristics of dyshoric capillary cerebral amyloid angiopathy. J Neuropathol Exp Neurol 69, 1158-1167.
19. Chamard L, Wallon D, Pijoff A., Berger E, Viennet G, Hannequin D., Magnin E. (2013) Amyloid-related imaging abnormalities in AbetaPP duplication carriers. J Alzheimers Dis 37, 789-793.